| Index | — | P/E | — | EPS (ttm) | -3.93 | Insider Own | 43.95% | Shs Outstand | 125.77M | Perf Week | 0.51% |
| Market Cap | 2.25B | Forward P/E | — | EPS next Y | -3.30 | Insider Trans | -0.20% | Shs Float | 94.24M | Perf Month | -26.96% |
| Enterprise Value | 1.64B | PEG | — | EPS next Q | -0.89 | Short Float | 13.11% | Perf Quarter | -38.02% | ||
| Income | -452.00M | P/S | 19.19 | EPS this Y | — | Short Ratio | 9.00 | Perf Half Y | -31.48% | ||
| Sales | 117.00M | P/B | 4.84 | EPS next Y | — | ROA | -48.92% | Short Interest | 12.36M | Perf YTD | -25.09% |
| Book/sh | 3.69 | P/C | 3.20 | EPS next 5Y | — | ROE | -87.98% | 52W High | 31.74 -42.03% | Perf Year | -11.59% |
| Cash/sh | 5.58 | P/FCF | — | EPS past 3/5Y | — | ROIC | -65.76% | 52W Low | 17.43 5.57% | Perf 3Y | 12.12% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 30.16% 25.93% | Gross Margin | 94.02% | Volatility | 4.69% 6.47% | Perf 5Y | -48.08% |
| Dividend TTM | — | EV/Sales | 14.05 | EPS Y/Y TTM | — | Oper. Margin | -415.38% | ATR (14) | 1.39 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 3.82 | Sales Y/Y TTM | -55.34% | Profit Margin | -386.32% | RSI (14) | 28.96 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.82 | EPS Q/Q | -858.47% | SMA20 | -15.64% | Beta | 1.07 | Target Price | 38.80 |
| Payout | 0.00% | Debt/Eq | 0.22 | Sales Q/Q | -74.37% | SMA50 | -27.81% | Rel Volume | 0.75 | Prev Close | 17.85 |
| Employees | 601 | LT Debt/Eq | 0.22 | Earnings | Nov 04 | SMA200 | -27.57% | Avg Volume | 1.83M | Price | 18.40 |
| IPO Date | Mar 14, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 19.21% 86.52% | Net Debt/EBITDA | — | Volume | 1,380,489 | Change | 3.08% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-21-26 | Reiterated | Truist Securities | Buy | $40 → $41 |
| Sep-08-26 | Reiterated | Truist Securities | Buy | $35 → $40 |
| Aug-10-26 | Reiterated | Morgan Stanley | Equal Weight | $22 → $23 |
| Aug-07-26 | Reiterated | Goldman Sachs | Buy | $34 → $42 |
| Aug-06-26 | Reiterated | Wedbush | Outperform | $35 → $43 |
| Jul-20-26 | Reiterated | HC Wainwright & Co. | Buy | $32 → $45 |
| May-18-26 | Reiterated | Truist Financial | Buy | $30 → $35 |
| May-11-26 | Reiterated | Morgan Stanley | Equal Weight | $20 → $22 |
| Apr-20-26 | Reiterated | Leerink Partners | Outperform | $49 → $47 |
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight | $26 → $23 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 117 | 247 | 258 | 117 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 7 | 10 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 110 | 237 | 258 | 117 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 106 | 110 | 120 | 117 | — | — | — | — | — | |
| Research and Development | 497 | 523 | 448 | 340 | — | — | — | — | — | |
| Other Operating Expense | -7 | -10 | 20 | 0 | — | — | — | — | — | |
| Operating Income | -486 | -386 | -330 | -340 | — | — | — | — | — | |
| Interest Expense | 23 | 8 | 4 | 2 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 57 | 41 | 51 | 41 | — | — | — | — | — | |
| Net Income Before Taxes | -452 | -353 | -283 | -301 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 1 | 6 | — | — | — | — | — | |
| Consolidated Net Income | -452 | -353 | -283 | -307 | — | — | — | — | — | |
| Net Income From Continuing Operations | -452 | -353 | -284 | -307 | — | — | — | — | — | |
| Net Income | -452 | -353 | -283 | -307 | — | — | — | — | — | |
| EPS (Recurring) | -3.93 | -3.29 | -3.14 | -4.15 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.93 | -3.29 | -3.14 | -4.15 | — | — | — | — | — | |
| EPS (Diluted) | -3.93 | -3.29 | -3.14 | -4.15 | — | — | — | — | — | |
| EBITDA | -419 | -335 | -269 | -291 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 19.82 | 10.32 | 5.19 | 12.08 | — | — | — | — | — | |
| Gross Margin | 94.02 | 95.95 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -415.38 | -156.28 | -127.91 | -290.60 | — | — | — | — | — | |
| Net Margin | -386.32 | -142.91 | -109.69 | -262.39 | — | — | — | — | — | |
| Shares Outstanding | 126 | 107 | 90 | 74 | — | — | — | — | — | |
| Market Capitalization | 2,318 | 2,550 | 1,340 | 1,413 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Azoy Alexander | Chief Accounting Officer | Aug 21 '26 | Sale | 30.00 | 2,827 | 84,810 | 39,581 | Aug 24 |
| Azoy Alexander | Chief Accounting Officer | Aug 21 '26 | Option Exercise | 15.44 | 2,827 | 43,649 | 42,408 | Aug 24 |
| Jaen Juan C. | President | Jul 10 '26 | Sale | 28.62 | 20,067 | 574,288 | 822,240 | Jul 13 |
| Jaen Juan C. | President | Jul 09 '26 | Sale | 30.05 | 48,502 | 1,457,631 | 842,307 | Jul 13 |
| Jaen Juan C. | President | Jun 24 '26 | Sale | 29.66 | 6,431 | 190,740 | 890,809 | Jun 24 |
| Jaen Juan C. | President | Jun 23 '26 | Sale | 27.73 | 15,764 | 437,100 | 897,240 | Jun 24 |
| Jaen Juan C. | President | Jun 22 '26 | Sale | 27.03 | 9,236 | 249,661 | 913,004 | Jun 24 |
| Tang Carolyn C. | General Counsel | Jun 11 '26 | Option Exercise | 2.57 | 34,090 | 87,748 | 184,607 | Jun 12 |
| Azoy Alexander | Chief Accounting Officer | Jun 01 '26 | Sale | 25.77 | 2,562 | 66,024 | 39,581 | Jun 01 |
| Goeltz II Robert C. | Chief Financial Officer | May 11 '26 | Sale | 25.63 | 7,763 | 198,966 | 84,161 | May 12 |
| Jaen Juan C. | President | Jan 05 '26 | Sale | 21.41 | 31,823 | 681,342 | 922,240 | Jan 07 |
| Goeltz II Robert C. | Chief Financial Officer | Dec 31 '25 | Sale | 23.38 | 6,552 | 153,186 | 67,924 | Jan 02 |
| Azoy Alexander | Chief Accounting Officer | Dec 18 '25 | Sale | 22.25 | 4,343 | 96,614 | 18,531 | Dec 18 |
| ROSEN TERRY J | Chief Executive Officer | Dec 17 '25 | Sale | 22.16 | 25,744 | 570,474 | 2,194,809 | Dec 18 |
| Markus Richard | Chief Medical Officer | Dec 17 '25 | Sale | 22.16 | 4,494 | 99,585 | 65,647 | Dec 18 |